Knowledge and attitude of community pharmacists toward biosimilar medicines: A cross-sectional study in Lebanon

Abstract

ObjectivesPharmacists are drug experts who can play a significant role in promoting the use of biosimilar medicines. Therefore, the aim of this study was to assess community pharmacists' knowledge and attitude toward biosimilars in Lebanon, as well as potential factors influencing their knowledge. MethodsA descriptive, cross-sectional study involving licensed community pharmacists in Lebanon was conducted using random sampling between January and July 2022. An electronic survey consisting of 30-closed ended questions was used, it included 10 questions to assess participants knowledge towards biosimilars and 10 attitudinal statements. A knowledge score was then calculated. A multivariable analysis was conducted to determine predictors of knowledge using binary logistic regression including all variables with p < 0.20 on univariate analysis. Statistical significance was set at p value < 0.05. Key findingsIn total, 354 community pharmacists completed this survey. The majority of participants 261 (73.7%) were knowledgeable, with only 54 (15.3%) answering all the questions correctly. The results of the multivariable analysis showed only a statistically significant association between knowledge and pharmacists who had taken a course or post-graduate training course about biosimilar drugs (OR = 2.213, 95% CI = 1.088–4.500, p-value = 0.028). The majority of pharmacists 314 (88.7%) agreed with the statement “Healthcare professionals should be further educated to eliminate potential misconceptions and integrate biosimilars into routine clinical practice.” ConclusionsOverall, community pharmacists in Lebanon had a good knowledge about biosimilars that was significantly associated with post-graduate training courses. Additionally, our participants had a generally favorable attitude toward biosimilars.